IRAK4 degrader KT-474 Phase 1 patient cohort amended to extend dosing from 14 to 28 days, enabling inclusion of exploratory clinical efficacy endpoints and extended safety monitoring
Clinical trials initiated for STAT3 (KT-333) and IRAKIMiD (KT-413) oncology programs
Pre-clinical data presented at AACR on first-in-class MDM2 degrader, KT-253, highlighting the potential benefit of degradation over inhibition and broader clinical opportunities; IND filing planned for 2H22
March 31, 2022 cash balance of approximately $523 million, providing cash runway into 2025
Company to hold quarterly results call at 8am EST (833-740-0921 or 409-937-8885, ID #2984916)
https://finance.yahoo.com/news/kymera-therapeutics-announces-first-quarter-110000366.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.